About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 858946, 13 pages
http://dx.doi.org/10.1155/2013/858946
Research Article

STAT6 siRNA Matrix-Loaded Gelatin Nanocarriers: Formulation, Characterization, and Ex Vivo Proof of Concept Using Adenocarcinoma Cells

1Department of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, 200 W. Kawili Street, Hilo, HI 96720, USA
2Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawai’i, 651 Ilalo Street, Honolulu, HI 96813, USA

Received 1 May 2013; Accepted 13 August 2013

Academic Editor: Kamla Pathak

Copyright © 2013 Susanne R. Youngren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Bagasra and K. R. Prilliman, “RNA interference: the molecular immune system,” Journal of Molecular Histology, vol. 35, no. 6, pp. 545–553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Rana, “Illuminating the silence: understanding the structure and function of small RNAs,” Nature Reviews Molecular Cell Biology, vol. 8, no. 1, pp. 23–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. H. M. Ali, G. Urbinati, M. Raouane, and L. Massaad-Massade, “Significance and applications of nanoparticles in siRNA delivery for cancer therapy,” Expert Review of Clinical Pharmacology, vol. 5, pp. 403–412, 2012.
  4. A. Tomkinson, A. Kanehiro, N. Rabinovitch, A. Joetham, G. Cieslewicz, and E. W. Gelfand, “The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 4, pp. 1283–1291, 1999. View at Scopus
  5. K. Nelms, A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul, “The IL-4 receptor: signaling mechanisms and biologic functions,” Annual Review of Immunology, vol. 17, pp. 701–738, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Woetmann, J. Brockdorff, P. Lovato et al., “Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2787–2791, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kato, H. Yoshidome, M. J. Edwards, and A. B. Lentsch, “Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6,” Inflammation Research, vol. 49, no. 6, pp. 275–279, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Iff, W. Wang, T. Sajic et al., “Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis,” Journal of Proteome Research, vol. 8, no. 10, pp. 4511–4524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Zhang, Y. Zhou, C. Xie et al., “STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells,” Cancer Letters, vol. 243, no. 1, pp. 38–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Das, C. P. Roth, L. M. Wasson, and J. K. Vishwanatha, “Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer,” Prostate, vol. 67, no. 14, pp. 1550–1564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Cui, L. Zhang, J. Luo et al., “Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer,” Oncogene, vol. 26, no. 29, pp. 4253–4260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Y. Cui, S. C. Yang, H. Dalwadi, S. Sharma, N. Cacalano, and S. Dubinett, “STAT6 mediates IL-4 inhibition of cyclooxygenase-2 (COX-2): defining native regulation of COX-2 to develop new targets for lung cancer chemoprevention,” Cancer Epidemiology Biomarkers & Prevention, vol. 13, pp. 1879S–1880S, 2004.
  13. R. Dubey, R. Chhabra, and N. Saini, “Small interfering RNA against transcription factor STAT6 leads to increased cholesterol synthesis in lung cancer cell lines,” PLoS ONE, vol. 6, no. 12, Article ID e28509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Aoudjehane, P. Podevin, O. Scatton et al., “Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway,” The FASEB Journal, vol. 21, no. 7, pp. 1433–1444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Martin, J. A. Innes, C. M. Lambert, C. M. Turnbull, and W. A. H. Wallace, “Hypersensitivity pneumonitis associated with leflunomide therapy,” Journal of Rheumatology, vol. 34, no. 9, pp. 1934–1937, 2007. View at Scopus
  16. J. R. Cortes, M. Perez-G, M. D. Rivas, and J. Zamorano, “Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3,” Journal of Immunology, vol. 179, no. 6, pp. 3881–3887, 2007. View at Scopus
  17. K. V. Glebova, A. V. Marakhonov, A. V. Baranova, and M. I. Skoblov, “Therapeutic siRNAs and non-viral systems for their delivery,” Molekuliarnaia Biologiia, vol. 46, pp. 371–386, 2012.
  18. R. K. Tekade, T. Dutta, A. Tyagi, A. C. Bharti, B. C. Das, and N. K. Jain, “Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy,” Journal of Drug Targeting, vol. 16, no. 10, pp. 758–772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Kayat, V. Gajbhiye, R. K. Tekade, and N. K. Jain, “Pulmonary toxicity of carbon nanotubes: a systematic report,” Nanomedicine, vol. 7, no. 1, pp. 40–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Gajbhiye, P. V. Kumar, R. K. Tekade, and N. K. Jain, “PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist,” European Journal of Medicinal Chemistry, vol. 44, no. 3, pp. 1155–1166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Dwivedi, R. K. Tekade, and N. K. Jain, “Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in Alzheimer's disease,” Current Nanoscience, vol. 9, pp. 46–55, 2013.
  22. B. D. Kurmi, J. Kayat, V. Gajbhiye, R. K. Tekade, and N. K. Jain, “Micro- and nanocarrier-mediated lung targeting,” Expert Opinion on Drug Delivery, vol. 7, no. 7, pp. 781–794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. K. Tekade, T. Dutta, V. Gajbhiye, and N. K. Jain, “Exploring dendrimer towards dual drug delivery: PH responsive simultaneous drug-release kinetics,” Journal of Microencapsulation, vol. 26, no. 4, pp. 287–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Kesharwani, V. Gajbhiye, R. K. Tekade, and N. K. Jain, “Evaluation of dendrimer safety and efficacy through cell line studies,” Current Drug Targets, vol. 12, no. 10, pp. 1478–1497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. G. S. Maheshwari, R. K. Tekade, G. Dharvekar, and D. K. Jain, “Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment,” Saudi Pharmaceutical Journal, vol. 20, no. 2, pp. 161–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Benfer and T. Kissel, “Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 80, no. 2, pp. 247–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Kaul and M. Amiji, “Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model,” Journal of Drug Targeting, vol. 12, no. 9-10, pp. 585–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Y. Yang, Y. Zheng, J. Y. Chen, et al., “Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection,” Colloids and Surfaces B, vol. 101, pp. 6–13, 2012, 2012 Elsevier B.V.
  29. S. Thakur, R. K. Tekade, P. Kesharwani, and N. K. Jain, “The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers,” Journal of Nanoparticle Research, vol. 15, p. 1625, 2013.
  30. R. K. Tekade, P. V. Kumar, and N. K. Jain, “Dendrimers in oncology: an expanding horizon,” Chemical Reviews, vol. 109, no. 1, pp. 49–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. K. Jain and R. K. Tekade, “Dendrimers for enhanced drug solubilization,” in Drug Delivery Strategies for Poorly Water-Soluble Drugs, pp. 373–409, John Wiley & Sons, New York, NY, USA, 2013.
  32. V. Gajbhiye, V. K. Palanirajan, R. K. Tekade, and N. K. Jain, “Dendrimers as therapeutic agents: a systematic review,” Journal of Pharmacy and Pharmacology, vol. 61, no. 8, pp. 989–1003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. N. Prajapati, R. K. Tekade, U. Gupta, V. Gajbhiye, and N. K. Jain, “Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam,” Molecular Pharmaceutics, vol. 6, no. 3, pp. 940–950, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Kesharwani, R. K. Tekade, V. Gajbhiye, K. Jain, and N. K. Jain, “Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison,” Nanomedicine, vol. 7, no. 3, pp. 295–304, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. R. S. Dhakad, R. K. Tekade, and N. K. Jain, “Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone,” Current Drug Delivery, vol. 10, no. 4, pp. 477–491, 2013.
  36. C. Coester, P. Nayyar, and J. Samuel, “In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 62, no. 3, pp. 306–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Coester, K. Langer, H. von Briesen, and J. Kreuter, “Gelatin nanoparticles by two step desolvation—a new preparation method, surface modifications and cell uptake,” Journal of Microencapsulation, vol. 17, no. 2, pp. 187–193, 2000. View at Scopus
  38. S. Balthasar, K. Michaelis, N. Dinauer, H. von Briesen, J. Kreuter, and K. Langer, “Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes,” Biomaterials, vol. 26, no. 15, pp. 2723–2732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. J. Lee, S. A. Khan, J. K. Park, and K. Lim, “Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation,” Bioprocess and Biosystems Engineering, vol. 35, no. 1-2, pp. 297–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Azarmi, Y. Huang, H. Chen et al., “Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 1, pp. 124–132, 2006. View at Scopus
  41. N. Ichite, M. Chougule, A. R. Patel, T. Jackson, S. Safe, and M. Singh, “Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer,” Molecular Cancer Therapeutics, vol. 9, no. 11, pp. 3003–3014, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Chougule, B. Padhi, and A. Misra, “Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics,” International Journal of Nanomedicine, vol. 2, pp. 675–688, 2007.
  43. R. R. Patlolla, M. Chougule, A. R. Patel, T. Jackson, P. N. V. Tata, and M. Singh, “Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers,” Journal of Controlled Release, vol. 144, no. 2, pp. 233–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, and D. Schubert, “Optimization of the preparation process for human serum albumin (HSA) nanoparticles,” International Journal of Pharmaceutics, vol. 257, no. 1-2, pp. 169–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Kriegel and M. Amiji, “Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease,” Journal of Controlled Release, vol. 150, no. 1, pp. 77–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Reif, F. Haque, and P. Guo, “Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells,” Nucleic Acid Therapeutics, vol. 22, pp. 428–437, 2012.
  47. S. Kennedy, D. Wang, and G. Ruvkun, “A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans,” Nature, vol. 427, no. 6975, pp. 645–649, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Ichite, M. B. Chougule, T. Jackson, S. V. Fulzele, S. Safe, and M. Singh, “Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer,” Clinical Cancer Research, vol. 15, no. 2, pp. 543–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Youngren, R. Mulik, B. Jun, P. Hoffmann, K. Morris, and M. Chougule, “Freeze-dried targeted mannosylated seleniumloaded nanoliposomes: development and evaluation,” AAPS PharmSciTech. In press.
  50. Y. Darcan-Nicolaisen, H. Meinicke, G. Fels et al., “Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice 1,” Journal of Immunology, vol. 182, no. 12, pp. 7501–7508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. F. W. Hoffmann, A. C. Hashimoto, L. A. Shafer, S. Dow, M. J. Berry, and P. R. Hoffmann, “Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols,” Journal of Nutrition, vol. 140, no. 6, pp. 1155–1161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. C. Society, Cancer Facts & Figures 2013, American Cancer Soceity, Atlanta, Ga, USA, 2013.
  53. D. H. Sterman, L. R. Kaiser, and S. M. Albelda, “Advances in the treatment of malignant pleural mesothelioma,” Chest, vol. 116, no. 2, pp. 504–520, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Chougule, A. R. Patel, P. Sachdeva, T. Jackson, and M. Singh, “Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer,” Lung Cancer, vol. 71, no. 3, pp. 271–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Saffari, F. H. Shirazi, M. A. Oghabian, and H. R. Moghimi, “Preparation and in-vitro evaluation of an antisense-containing cationic Liposome against non-small cell lung cancer: a comparative preparation study,” Iranian Journal of Pharmaceutical Research, vol. 12, pp. 1–8, 2013.
  56. J. Remon, P. Lianes, S. Martinez, M. Velasco, R. Querol, and M. Zanui, “Malignant mesothelioma: new insights into a rare disease,” Cancer Treatment Reviews, vol. 39, no. 6, pp. 584–591, 2013.
  57. P. A. Jänne, A. J. Wozniak, C. P. Belani et al., “Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program,” Journal of Thoracic Oncology, vol. 1, pp. 506–512, 2006.
  58. S. Kommareddy and M. M. Amiji, “Protein nanospheres for gene delivery,” Cold Spring Harbor Protocols, 2008. View at Publisher · View at Google Scholar
  59. J. Xu, S. Ganesh, and M. Amiji, “Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery,” International Journal of Pharmaceutics, vol. 427, no. 1, pp. 21–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Won, S. Yoon, C. H. Sonn, K. Lee, and Y. Kim, “Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery,” ACS Nano, vol. 5, no. 5, pp. 3839–3848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. T. R. Keenan, “Gelatin,” in Polymer Science: A Comprehensive Reference, M. Moeller and K. Matyjaszewski, Eds., vol. 10, pp. 237–247, Elsevier BV, Amsterdam, The Netherland, 2012.
  62. K. Zwiorek, C. Bourquin, J. Battiany et al., “Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides,” Pharmaceutical Research, vol. 25, no. 3, pp. 551–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Kushibiki, R. Tomoshige, Y. Fukunaka, M. Kakemi, and Y. Tabata, “In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents,” Journal of Controlled Release, vol. 90, no. 2, pp. 207–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Obata, T. Nishino, T. Kushibiki et al., “HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice,” Acta Biomaterialia, vol. 8, pp. 2688–2696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. P. A. Kadengodlu, T. Aigaki, H. Abe, and Y. Ito, “Cationic cholesterol-modified gelatin as an in vitro siRNA delivery vehicle,” Molecular BioSystems, vol. 9, pp. 965–968, 2013.
  66. S. Kommareddy and M. Amiji, “Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione,” Bioconjugate Chemistry, vol. 16, no. 6, pp. 1423–1432, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Lemieux, N. Guérin, G. Paradis et al., “A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle,” Gene Therapy, vol. 7, no. 11, pp. 986–991, 2000. View at Scopus
  68. C. Bourquin, C. Wurzenberger, S. Heidegger et al., “Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response,” Journal of Immunotherapy, vol. 33, no. 9, pp. 935–944, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Saito and Y. Tabata, “Preparation of gelatin hydrogels incorporating small interfering RNA for the controlled release,” Journal of Drug Targeting, vol. 20, pp. 864–872, 2012.
  70. S. Giraudier, D. Hellio, M. Djabourov, and V. Larreta-Garde, “Influence of weak and covalent bonds on formation and hydrolysis of gelatin networks,” Biomacromolecules, vol. 5, no. 5, pp. 1662–1666, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Alameh, D. DeJesus, M. Jean, et al., “Low molecular weight chitosan nanoparticulate system at low N : P ratio for nontoxic polynucleotide delivery,” International Journal of Nanomedicine, vol. 7, pp. 1399–1414, 2012.
  72. E. S. Taheri, M. Jahanshahi, and M. T. H. Mosavian, “Preparation, characterization and optimization of egg albumin nanoparticles as low molecular-weight drug delivery vehicle,” Particle & Particle Systems Characterization, vol. 29, pp. 211–222, 2012.
  73. D. Braga, F. Grepioni, L. Maini, and M. Polito, “Crystal polymorphism and multiple crystal forms,” Structure and Bonding, vol. 132, pp. 25–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Asghari and F. Esmaeilzadeh, “Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach,” International Journal of Pharmaceutics, vol. 433, pp. 149–156, 2012.
  75. M. Jahanshahia, M. H. Sanati, and Z. Babaeia, “Optimization of parameters for the fabrication of gelatin nanoparticles by the Taguchi robust design method,” Journal of Applied Statistics, vol. 35, no. 12, pp. 1345–1353, 2008. View at Publisher · View at Google Scholar
  76. P. Severino, M. H. A. Santana, and E. B. Souto, “Optimizing SLN and NLC by 22 full factorial design: effect of homogenization technique,” Materials Science and Engineering C, vol. 32, pp. 1375–1379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. M. D. Bhavsar, S. B. Tiwari, and M. M. Amiji, “Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design,” Journal of Controlled Release, vol. 110, no. 2, pp. 422–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Dillen, J. Vandervoort, G. van den Mooter, L. Verheyden, and A. Ludwig, “Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles,” International Journal of Pharmaceutics, vol. 275, no. 1-2, pp. 171–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. P. S. C. Sarsambi K and K. P. Rao, “Spectrophotometric estimation of gemcitabine in bulk drug and its formulation,” IJPI’s Journal of Analytical Chemistry, vol. 1, pp. 18–24, 2011.
  80. S. Wadher, P. Pathankar, M. Puranik, R. Ganjiwale, and P. Yeole, “Simultaneous spectrophotometric estimation of paracetamol and metoclopramide hydrochloride in solid dosage form,” Indian Journal of Pharmaceutical Sciences, vol. 70, no. 3, pp. 393–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Dastmalchi, M. R. Rashidi, and M. Rassi, “Simultaneous determination of the pKa and octanol/water partition coefficient (Pm) of acetaminophen,” Journal of School of Pharmacy, Medical Sciences University of Tehran, vol. 4, pp. 7–14, 1995.
  82. M. Rahimnejad, M. Jahanshahi, and G. D. Najafpour, “Production of biological nanoparticles from bovine serum albumin for drug delivery,” African Journal of Biotechnology, vol. 5, no. 20, pp. 1918–1923, 2006. View at Scopus
  83. H. Maeda, H. Nakamura, and J. Fang, “The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo,” Advanced Drug Delivery Reviews, vol. 65, pp. 71–79, 2013.
  84. J. Kreuter, “Peroral administration of nanoparticles,” Advanced Drug Delivery Reviews, vol. 7, no. 1, pp. 71–86, 1991. View at Publisher · View at Google Scholar · View at Scopus
  85. S. A. Khan and M. Schneider, “Improvement of nanoprecipitation technique for preparation of gelatin nanoparticles and potential macromolecular drug loading,” Macromolecular Bioscience, vol. 13, pp. 455–463, 2013.
  86. M. B. Chougule, B. K. Padhi, and A. Misra, “Nano-liposomal dry powder inhaler of amiloride hydrochloride,” Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 3001–3009, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. Q. Gan and T. Wang, “Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release,” Colloids and Surfaces B, vol. 59, no. 1, pp. 24–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. Z. Hao, B. Qu, Y. Wang et al., “Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres,” Drug Development and Industrial Pharmacy, vol. 37, no. 12, pp. 1422–1428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Zaupa, A. T. Neffe, B. F. Pierce, U. Nöchel, and A. Lendlein, “Influence of tyrosine-derived moieties and drying conditions on the formation of helices in gelatin,” Biomacromolecules, vol. 12, no. 1, pp. 75–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Sundar, J. Kundu, and S. C. Kundu, “Biopolymeric nanoparticles,” Science and Technology of Advanced Materials, vol. 11, Article ID 014104, 2010. View at Publisher · View at Google Scholar
  91. P. P. Karmali and D. Simberg, “Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems,” Expert Opinion on Drug Delivery, vol. 8, no. 3, pp. 343–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Shah, Hypoxia in tumor angiogenesis and metastasis: evaluation of VEGFand MMP over-expression and down-regulation of HIF-1a with RNAi in hypoxic tumor cells [M.S. thesis], Northeastern University, Boston, Mass, USA, 2010.
  93. G. Kaul and M. Amiji, “Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery,” Pharmaceutical Research, vol. 19, no. 7, pp. 1061–1067, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. K. L. Douglas, C. A. Piccirillo, and M. Tabrizian, “Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 68, no. 3, pp. 676–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Greenspan, E. P. Mayer, and S. D. Fowler, “Nile red: a selective fluorescent stain for intracellular lipid droplets,” Journal of Cell Biology, vol. 100, no. 3, pp. 965–973, 1985. View at Scopus
  96. P. Greenspan and S. D. Fowler, “Spectrofluorometric studies of the lipid probe, nile red,” Journal of Lipid Research, vol. 26, no. 7, pp. 781–789, 1985. View at Scopus
  97. B. H. Li, S. B. Xu, F. Li et al., “Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo,” Cellular Signalling, vol. 24, no. 3, pp. 718–725, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. A. L. Wurster, T. Tanaka, and M. J. Grusby, “The biology of Stat4 and Stat6,” Oncogene, vol. 19, no. 21, pp. 2577–2584, 2000. View at Scopus
  99. D. Baus, F. Nonnenmacher, S. Jankowski et al., “STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line,” Leukemia, vol. 23, no. 10, pp. 1885–1893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Kriegel, H. Attarwala, and M. Amiji, “Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract,” Advanced Drug Delivery Reviews, vol. 65, no. 6, pp. 891–901, 2013.